Clinical trialEPhase 1Withdrawn
Biological Effect of Warfarin on Pancreatic Cancer
- Outcome
- Stopped earlyno accrual for over 12 months (Enrollment)
- Phase
- EPhase 1
- Status
- Withdrawn
- Study type
- Interventional
- Start
- 15 May 2019
- Expected end
- June 2022
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Determine change in AXL pathway
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 March 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
There is emerging evidence from pre-clinical models that Axl activation is critical for the tumorigenesis and metastasis of pancreatic cancer. Warfarin is a readily available drug in the clinical setting and could be easily, safely, and quickly used in patients in combination with known cytotoxic chemotherapies to improve overall survival. Oral warfarin has been well tolerated in both prophylaxis for catheter-associated thrombosis and in advanced pancreatic cancer patients. The aim of this trial is to confirm the preclinical evidence that warfarin affects AXL pathway in patients with pancreatic cancer. This will validate the effect of escalating doses of warfarin on circulating biomarkers of AXL.